Beyond CBD and THC: Cannabigerol (CBG) as an Emerging Neuropsychiatric Drug Candidate

Cannabigerol (CBG) is a non-intoxicating phytocannabinoid under investigation as a neuropsychiatric drug candidate. Although historically studied primarily for its role in cannabinoid biosynthesis, CBG has a multitarget pharmacological profile distinct from those of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC). Experimental studies implicate cannabinoid receptors, α2A-adrenoceptors, 5-HT1A receptors, transient receptor potential channels, peroxisome proliferator-activated receptor-γ, and voltage-gated sodium channels, alongside effects on neuroinflammation, oxidative stress, neuronal survival, and excitability. These findings support investigation across several neuropsychiatric conditions, but their clinical relevance remains uncertain. Human studies have begun to characterize oral pharmacokinetics, the influence of food and formulation on systemic exposure, and acute tolerability. A single-dose controlled study of healthy adults reported preliminary effects on anxiety and stress, whereas a repeated-dose randomized trial in participants with problematic sleep found no superiority over placebo on its primary outcome. Brain exposure, target engagement, exposure–response relationships, drug interactions, therapeutic dosing, and long-term safety remain insufficiently defined. This review critically evaluates the pharmacological, preclinical, and human evidence for CBG and identifies the barriers to clinical translation. Despite a plausible experimental rationale, efficacy has not been established for any neuropsychiatric disorder.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-18
DOI
https://doi.org/10.3390/biomedicines14112667
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Beyond CBD and THC: Cannabigerol (CBG) as an Emerging Neuropsychiatric Drug Candidate

José Alexandre S. Crippa, João Francisco Cordeiro Pedrazzi, Jaime E. C. Hallak
2 links
Biomedicines
Cannabis and Cannabinoid Research
article

Beyond CBD and THC: Cannabigerol (CBG) as an Emerging Neuropsychiatric Drug Candidate

José Alexandre S. Crippa, João Francisco Cordeiro Pedrazzi, Jaime E. C. Hallak
article en

Abstract

Cannabigerol (CBG) is a non-intoxicating phytocannabinoid under investigation as a neuropsychiatric drug candidate. Although historically studied primarily for its role in cannabinoid biosynthesis, CBG has a multitarget pharmacological profile distinct from those of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC). Experimental studies implicate cannabinoid receptors, α2A-adrenoceptors, 5-HT1A receptors, transient receptor potential channels, peroxisome proliferator-activated receptor-γ, and voltage-gated sodium channels, alongside effects on neuroinflammation, oxidative stress, neuronal survival, and excitability. These findings support investigation across several neuropsychiatric conditions, but their clinical relevance remains uncertain. Human studies have begun to characterize oral pharmacokinetics, the influence of food and formulation on systemic exposure, and acute tolerability. A single-dose controlled study of healthy adults reported preliminary effects on anxiety and stress, whereas a repeated-dose randomized trial in participants with problematic sleep found no superiority over placebo on its primary outcome. Brain exposure, target engagement, exposure–response relationships, drug interactions, therapeutic dosing, and long-term safety remain insufficiently defined. This review critically evaluates the pharmacological, preclinical, and human evidence for CBG and identifies the barriers to clinical translation. Despite a plausible experimental rationale, efficacy has not been established for any neuropsychiatric disorder.

BiomedicinesVol. 14(11)
Universidade de São Paulo (BR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR), Clinics Hospital of Ribeirão Preto (BR)
Good health and well-being
Cannabis and Cannabinoid Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon